Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Hypertension, Essential
Interventions: Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg, Nifedipine GITS (Adalat, BAYA1040), 30 mg, Nifedipine GITS (Adalat, BAYA1040), 60 mg, Placebo, Candesartan cilexetil (Atacand), 16 mg, Candesartan cilexetil (Atacand), 32 mg; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 23
States / cities: Mobile, Alabama • Los Angeles, California • Coral Gables, Florida + 18 more

Conditions: Congenital Fibrinogen Deficiency, Afibrinogenemia
Interventions: Octafibrin, Haemocomplettan® P or RiaSTAPTM; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Aurora, Colorado • New Hyde Park, New York

Conditions: Anxiety, Panic Disorder
Interventions: Freespira Breathing System; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lupus Erythematosus, Systemic, Lupus Erythematosus, Fatigue
Interventions: RAYOS, Prednisone; Drug
Lead sponsor: Ampel BioSolutions, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 21
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 15 more

Conditions: Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 96
States / cities: Mobile, Alabama • Mesa, Arizona • Oro Valley, Arizona + 93 more

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions: FWY003, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 16
States / cities: Huntington Beach, California • Sacramento, California • Santa Barbara, California + 12 more

Conditions: End Stage Renal Disease, Chronic Kidney Disease
Interventions: Cognitive Function Testing-10 Tests, Sleep Assessment Testing, Periodic Leg Movement Syndrome Assessment; Other
Lead sponsor: Satellite Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Mountain View, California

Conditions: Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more

Conditions: Pain, Spine Fusion
Interventions: Preoperative Ultrasound TLIP, Intraoperative TLIP; Procedure
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Type 1 Diabetes, Eating Disorders
Interventions: Diabetes Body Project, Educational Group; Behavioral
Lead sponsor: Oslo University Hospital; Other
Eligibility: 14 Years to 35 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Stanford, California • Boston, Massachusetts

Conditions: Hypertension
Interventions: LFF269, Eplerenone, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 11
States / cities: Anaheim, California • Fort Myers, Florida • Miramar, Florida + 7 more

Conditions: Vitamin D Deficiency
Interventions: vitamin D, Placebo; Dietary Supplement · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 47 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK5784283, Placebo, Standard of care; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Doral, Florida • Derby, Kansas • Lake Charles, Louisiana + 4 more

Conditions: Chronic Kidney Diseases, Eye Diseases, Cardiac Disease, Surgery, Low Back Pain
Interventions: Multicomponent Physician Performance Peer-Comparison Feedback Intervention; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 5,000,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rabies
Interventions: CL184, HRIG, Placebo matching CL184; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Traumatic Brain Injury, Head Injury, Head Injuries, Closed, Brain Hemorrhage, Traumatic, Brain Edema, Intracranial Edema
Interventions: Road-to-recovery; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Treatment Resistant Depression, Treatment Resistant Depression (TRD)
Interventions: Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS, Oral Placebo; Device · Drug
Lead sponsor: NeuroRx, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Sarasota, Florida • West Palm Beach, Florida • Belmont, Massachusetts

Conditions: Type II Diabetes Mellitus
Interventions: Resonator Device; Device
Lead sponsor: pico-tesla Magnetic Therapies, LLC; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Littleton, Colorado

Conditions: Invasive Candidiasis
Interventions: therapy duration; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 120 Days and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 21
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 17 more

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 44
States / cities: Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more

Conditions: Degenerative Disc Disease, Spondylolisthesis
Interventions: Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules, Iliac crest autograft; Device · Other
Lead sponsor: BioSurface Engineering Technologies, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 6
States / cities: Durango, Colorado • Washington D.C., District of Columbia • Kansas City, Kansas + 3 more

Conditions: Cancer, Sickle Cell Disease
Interventions: Text messaging, Questionnaire, Interviews; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 10 Years to 17 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Diabetes Mellitus Type 2
Interventions: insulin glargine, metformin, taspoglutide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,072 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 74
States / cities: Phoenix, Arizona • Searcy, Arkansas • Concord, California + 63 more

Conditions: HIV
Interventions: Post test video; Behavioral
Lead sponsor: North Bronx Healthcare Network; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens

A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE

A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Comparison of Dialysis Therapies on Cognitive Function

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Randomized Controlled Comparison of Pre-op TLIP vs Intra-op TLIP

Multi-Site Eating Disorder Prevention Program for Type 1 Diabetes

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Comparison of 25-hydroxy Vitamin D Level in Caucasian Women Receiving Vitamin D Supplementation and Not Receiving Supplementation: a Randomized Controlled Trial.

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

Smarter Care Virginia, Examining Low-Value Care in Virginia

A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

Setting Families on a Positive Path to Recovery After Pediatric TBI: Road-to-Recovery

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

Application of Magnetic Fields as Adjunctive Treatment for Type II Diabetes

Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Pilot Study to Assess Safety/Preliminary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery

The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

A Theory Based HIV Prevention Video For Rapid HIV Testing: A Randomized Trial